Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab Publishes 2020 Annual Report

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

Amgen

Regeneron Pharmaceuticals

Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals. The post The $12 Billion Market That Has Biotech Stocks Hijacking The Immune System appeared first on Investor's Business Daily.

The $12 Billion Market That Has Biotech Stocks Hijacking The Immune System

Genmab (NASDAQ: GMAB) and Seagen Inc (NASDAQ: SGEN) have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The submission is based on the innovaTV 204 pivotal Phase 2 single-arm trial results evaluating tisotumab vedotin as monotherapy in this setting.

Genmab, Seagen File US Application For Tisotumab Vedotin In Cervical Cancer Setting

Seagen

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The submission is based on the results

Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Annexon, Inc

ASA Gold and Precious Metals Ltd

Blackrock Health Sciences Trust

BlackRock Health Sciences Trust II

BlackRock Science & Technology

BlackRock Science and Technology Trust II

Kymera Therapeutics

Masimo

Oak Street Health

Sigilon Therapeutics

Taysha Gene Therapies

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments.

BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential

Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)

Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie

Media Release Copenhagen, Denmark, January 6, 2021

Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference

Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.

Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug

Media Release COPENHAGEN, Denmark, Jan. 04, 2021

Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast.

Genmab: An European R&D Behemoth With Long-Term Potential

 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations

Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

Genmab Announces Enapotamab Vedotin Update

Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Media Release Copenhagen, Denmark, November 5, 2020

Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis

Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript

November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020

Genmab Announces Financial Results for the First Nine Months of 2020

Media Release Copenhagen, Denmark, November 4, 2020

Genmab Announces Data to be Presented at 2020 ASH Annual Meeting

ADC Therapeutics

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020

Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis

     Media Release Copenhagen, Denmark, October 14, 2020

Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020

Genmab: Still A Rising Star In Biotech, But Legal Dispute May Slow Down Growth Trajectory In The Near Term

News for Genmab - ADR Stock (GMAB)